South African strain
-
Previous infection seems not to offer protection from infection with new strain - at all. (Though maybe severity?)
But what is even more ominous is preliminary data from Novovax trial in South Africa. Previous infection did not protect against reinfection with variant strain: rates of COVID-19 among placebo group 7 days post-dose 1:
Seronegative: 3.9% (58/1494)
Seropositive: 3.9% (26/674)
7/ -
Fear not, the superior British strain will defeat the pathetic South African strain.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Register Login